Poly(ADP-ribose) polymerase inhibitors (PARPi) exploit synthetic lethality to treat BRCA1/2-mutated ovarian cancer, yet clinical responses are often incomplete and resistance frequently emerges. PARPi exert cytotoxic effects by inhibiting single-strand break repair and trapping PARP on DNA, which impedes replication fo...
Na Li, Kousalya Lavudi, Qian-Yun Ge et al.· Cancer Research· 0 citations
OBJECTIVES
Gynecologic cancers are marked by racial and socioeconomic disparities. As oncology care becomes increasingly digital, inequities in broadband and digital resources may exacerbate survival gaps. This study evaluated associations between digital inequity, measured by the Digital Divide Index, and survival amo...
Julia Chalif, Laura M. Chambers, Caitlin E. Meade et al.· International Journal of Gyn...· 0 citations
Objective(s): To evaluate the association of the Prognostic Nutritional Index (PNI) and Nutritional Risk Index (NRI) with immune-related adverse events, immunotherapy response, and oncologic outcomes. Methods: This study is an IRB-approved retrospective, single-institution cohort study in patients with CC treated with...
Julia Chalif, Molly A. Morton, Eric M. McLaughlin et al.· Gynecologic Oncology Reports· 0 citations
OBJECTIVES
To identify patient, provider, and system-level factors associated with delayed diagnosis of vulvar squamous cell cancer (SCC).
METHODS
An IRB-approved retrospective single-institution cohort study was conducted in patients with vulvar SCC diagnosed from 2009 to 2020. Patients were compared by time from sy...
Julia C. Sakach, Molly A Morton, Jessica Velasquez et al.· Gynecologic Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
